These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 14988389

  • 1. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB.
    Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
    [Abstract] [Full Text] [Related]

  • 2. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
    Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B.
    Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
    [Abstract] [Full Text] [Related]

  • 3. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
    Bai X, Miao D, Li J, Goltzman D, Karaplis AC.
    Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
    [Abstract] [Full Text] [Related]

  • 4. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
    Bielesz B.
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
    [Abstract] [Full Text] [Related]

  • 5. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23.
    Marsell R, Krajisnik T, Göransson H, Ohlsson C, Ljunggren O, Larsson TE, Jonsson KB.
    Nephrol Dial Transplant; 2008 Mar; 23(3):827-33. PubMed ID: 17911089
    [Abstract] [Full Text] [Related]

  • 6. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD.
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [Abstract] [Full Text] [Related]

  • 7. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
    Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, Hurley MM.
    J Biol Chem; 2010 Jan 22; 285(4):2834-46. PubMed ID: 19933269
    [Abstract] [Full Text] [Related]

  • 8. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
    Liu S, Gupta A, Quarles LD.
    Curr Opin Nephrol Hypertens; 2007 Jul 22; 16(4):329-35. PubMed ID: 17565275
    [Abstract] [Full Text] [Related]

  • 9. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice.
    Tomoe Y, Segawa H, Shiozawa K, Kaneko I, Tominaga R, Hanabusa E, Aranami F, Furutani J, Kuwahara S, Tatsumi S, Matsumoto M, Ito M, Miyamoto K.
    Am J Physiol Renal Physiol; 2010 Jun 22; 298(6):F1341-50. PubMed ID: 20357029
    [Abstract] [Full Text] [Related]

  • 10. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD.
    Am J Physiol Endocrinol Metab; 2007 Dec 22; 293(6):E1636-44. PubMed ID: 17848631
    [Abstract] [Full Text] [Related]

  • 11. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
    Kumar R.
    Curr Opin Nephrol Hypertens; 2002 Sep 22; 11(5):547-53. PubMed ID: 12187320
    [Abstract] [Full Text] [Related]

  • 12. Fibroblast growth factor 23 and its receptors.
    Yu X, White KE.
    Ther Apher Dial; 2005 Aug 22; 9(4):308-12. PubMed ID: 16076372
    [Abstract] [Full Text] [Related]

  • 13. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD.
    Am J Physiol Endocrinol Metab; 2003 Jul 22; 285(1):E1-9. PubMed ID: 12791601
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK, Lyles KW, Haussler MR, Harrelson JM.
    J Clin Invest; 1980 Nov 22; 66(5):1020-32. PubMed ID: 6253520
    [Abstract] [Full Text] [Related]

  • 15. FGF23 and disorders of phosphate homeostasis.
    Yu X, White KE.
    Cytokine Growth Factor Rev; 2005 Apr 22; 16(2):221-32. PubMed ID: 15863037
    [Abstract] [Full Text] [Related]

  • 16. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H.
    N Engl J Med; 2003 Apr 24; 348(17):1656-63. PubMed ID: 12711740
    [Abstract] [Full Text] [Related]

  • 17. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
    Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC.
    Biochem Biophys Res Commun; 2001 Jun 22; 284(4):977-81. PubMed ID: 11409890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.
    Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B.
    Am J Pathol; 2006 Dec 22; 169(6):2161-70. PubMed ID: 17148678
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.